New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AIM ImmunoTech Inc. (AIM) vs Reviva Pharmaceuticals Holdings, Inc. (RVPH)

AIM ImmunoTech Inc. and Reviva Pharmaceuticals Holdings, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Reviva Pharmaceuticals Holdings, Inc. are of similar size ($5.0M and $4.8M). Reviva Pharmaceuticals Holdings, Inc. has the higher net margin (0.00% vs −15,526.4%) and the higher return on invested capital (0.00% vs −5,687.5%). Across the 13 metrics below, Reviva Pharmaceuticals Holdings, Inc. leads on 9 and AIM ImmunoTech Inc. on 4.

Valuation

Metric AIM RVPH Biotechnology median
P/E n/m n/m 8.26
P/S 42.85 n/m 9.20
P/B 0.55 0.28 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA 0.26 0.68 0.67
EV/Sales (28.62) n/m 9.05
Earnings yield (2,206.08%) (69.14%) (34.24%)
Free cash flow yield (322.03%) (375.81%) (24.77%)

Profitability

Metric AIM RVPH Biotechnology median
Gross margin 38.46% — 70.18%
Operating margin (12,800.00%) 0.00% 0.00%
Net margin (15,526.37%) 0.00% 0.00%
Free cash flow margin (13,792.31%) 0.00% 0.00%
Return on equity (2,828.63%) (128.32%) (51.58%)
Return on assets (185.36%) (68.78%) (45.91%)
Return on invested capital (5,687.50%) 0.00% 0.00%

Growth

Metric AIM RVPH Biotechnology median
Revenue growth (TTM) (18.75%) — 7.20%
EPS growth (last fiscal year) 72.19% 69.56% 29.04%
Revenue growth, 5-year CAGR (11.60%) — 9.48%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM RVPH Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.75 3.39 4.83
Net debt to EBITDA 0.22 0.71 1.01

Dividend

Metric AIM RVPH Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric AIM RVPH Biotechnology median
Market cap 4.79m 5.00m 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack